SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
Phase 1-2 dose escalation randomized study in patients with intermediate or high risk
myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). The Dose Escalation
Segment will evaluate the biological activity, preliminary safety and efficacy of SGI-110
with two dosing schedules in MDS and AML patients while the Dose Expansion Segment will
further evaluate safety and efficacy at the biological effective dose (BED) or maximum
tolerated dose (MTD)as defined in the Dose Escalation Segment.